174 related articles for article (PubMed ID: 32770051)
1. Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis.
Derman BA; Jasielec J; Langerman SS; Zhang W; Jakubowiak AJ; Chiu BC
Blood Cancer J; 2020 Aug; 10(8):80. PubMed ID: 32770051
[TBL] [Abstract][Full Text] [Related]
2. Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities.
Guman T; Sykora J
Bratisl Lek Listy; 2024; 125(1):9-11. PubMed ID: 38041839
[TBL] [Abstract][Full Text] [Related]
3. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
[TBL] [Abstract][Full Text] [Related]
4. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents.
Merz M; Neben K; Raab MS; Sauer S; Egerer G; Hundemer M; Hose D; Kunz C; Heiß C; Ho AD; Goldschmidt H; Hillengass J
Ann Oncol; 2014 Jan; 25(1):189-95. PubMed ID: 24356629
[TBL] [Abstract][Full Text] [Related]
5. Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicine.
Shimazu Y; Mizuno S; Fuchida SI; Suzuki K; Tsukada N; Hanagaishi A; Itagaki M; Kataoka K; Kako S; Sakaida E; Yoshioka S; Iida S; Doki N; Oyake T; Ichinohe T; Kanda Y; Astuta Y; Takamatsu H;
Cancer Sci; 2021 Dec; 112(12):5034-5045. PubMed ID: 34644446
[TBL] [Abstract][Full Text] [Related]
6. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
7. The impact of race on outcomes of autologous transplantation in patients with multiple myeloma.
Verma PS; Howard RS; Weiss BM
Am J Hematol; 2008 May; 83(5):355-8. PubMed ID: 18186525
[TBL] [Abstract][Full Text] [Related]
8. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
[TBL] [Abstract][Full Text] [Related]
9. Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma.
Hari PN; Majhail NS; Zhang MJ; Hassebroek A; Siddiqui F; Ballen K; Bashey A; Bird J; Freytes CO; Gibson J; Hale G; Holmberg L; Kamble R; Kyle RA; Lazarus HM; LeMaistre CF; Loberiza F; Maiolino A; McCarthy PL; Milone G; Omondi N; Reece DE; Seftel M; Trigg M; Vesole D; Weiss B; Wiernik P; Lee SJ; Rizzo JD; Mehta P
Biol Blood Marrow Transplant; 2010 Mar; 16(3):395-402. PubMed ID: 19922808
[TBL] [Abstract][Full Text] [Related]
10. Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis.
Ailawadhi S; Parikh K; Abouzaid S; Zhou Z; Tang W; Clancy Z; Cheung C; Zhou ZY; Xie J
Blood Adv; 2019 Oct; 3(20):2986-2994. PubMed ID: 31648322
[TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
13. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.
Mina R; Petrucci MT; Corradini P; Spada S; Patriarca F; Cerrato C; De Paoli L; Pescosta N; Ria R; Malfitano A; Musto P; Baldini L; Guglielmelli T; Gamberi B; Mannina D; Benevolo G; Zambello R; Falcone AP; Palumbo A; Nagler A; Calafiore V; Hájek R; Spencer A; Boccadoro M; Bringhen S
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):533-540. PubMed ID: 29910180
[TBL] [Abstract][Full Text] [Related]
14. The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Royle KL; O'Connor S; Cairns DA; Ashcroft AJ; Williams CD; Hockaday A; Cavenagh JD; Snowden JA; Ademokun D; Tholouli E; Andrews VE; Jenner M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Drayson MT; Brown JM; Morris TCM;
Br J Haematol; 2019 May; 185(3):450-467. PubMed ID: 30729512
[TBL] [Abstract][Full Text] [Related]
15. Superior Survival in African American Patients Who Underwent Autologous Stem Cell Transplantation for Multiple Myeloma.
Sweiss K; Oh A; Calip GS; Rondelli D; Patel P
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e506-e511. PubMed ID: 31231013
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
17. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
Cook G; Williams C; Brown JM; Cairns DA; Cavenagh J; Snowden JA; Ashcroft AJ; Fletcher M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Chalmers A; O'Connor S; Drayson MT; Morris TC;
Lancet Oncol; 2014 Jul; 15(8):874-85. PubMed ID: 24948586
[TBL] [Abstract][Full Text] [Related]
18. Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes.
Mohan M; Susanibar-Adaniya S; Buros A; Crescencio JCR; Burgess MJ; Lusardi K; Davies F; Morgan G; Vanrhee F; Zangari M; Schinke C; Thanendrarajan S; Kothari A
Transpl Infect Dis; 2019 Apr; 21(2):e13052. PubMed ID: 30689291
[TBL] [Abstract][Full Text] [Related]
19. Survival analysis of transplant-eligible newly-diagnosed multiple myeloma patients harboring t(4;14), t(14;16), and/or del(17p) in the real-world setting.
Garrido D; Slavutsky I; Riva E;
Curr Probl Cancer; 2023 Feb; 47(1):100916. PubMed ID: 36473780
[TBL] [Abstract][Full Text] [Related]
20. Autologous stem cell transplantation for multiple myeloma: Long-term results.
Kumar L; Boya RR; Pai R; Harish P; Mookerjee A; Sainath B; Patekar MB; Sahoo RK; Malik PS; Sharma OD; Gupta R
Natl Med J India; 2016; 29(4):192-199. PubMed ID: 28050994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]